

TFW 1614

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/580,443
Filing Date	May 23, 2006
First Named Inventor	Joachim Moormann
Art Unit	1614
Examiner Name	
Attorney Docket Number	RO4245US (#90568)

Total Number of Pages in This Submission

ENCLOSURES (Check all that apply)

- ☐ Fee Transmittal Form
- ☐ Fee Attached
- ☐ Amendment/Reply
 - ☐ After Final
 - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Reply to Missing Parts/Incomplete Application
 - ☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation
- ☐ Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
- ☐ Landscape Table on CD

- ☐ After Allowance Communication to TC
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) (please identify below):
prior art documents and return postcard receipt

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	D. Peter Hochberg Co., L.P.A.		
Signature			
Printed name	D. Peter Hochberg		
Date	January 30, 2007	Reg. No.	24,603

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Sean Mellino	Date	01/30/2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



CERTIFICATE OF MAILING

I hereby certify that this document is being deposited with the United States Postal Service as First Class mail in an envelope addressed: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date noted below:

Date: 1/30/07

Sean Mellino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Joachim Moormann, et al.
Serial No. : 10/580,443
Filing Date : May 23, 2006
Examiner :
Group Art Unit : 1614
Title : USE OF DEOXYPEGANINE FOR TREATING
SCHIZOPHRENIC PSYCHOSES
Attorney File : RO4245US (#90568)

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97**

Mail Stop Amendment
Commissioner for Patents
P O Box 1450
Alexandria, Virginia, 22313-1450

Dear Sir,

Under the provision of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant would like to call the Examiner's attention to the references listed on the attached Form PTO-1449 which are originally set forth in specification of the present application. Copies of any U.S. patent or published application references are not enclosed. Copies of any non-U.S. patent references and non-patent references are enclosed herewith, unless indicated otherwise.

In accordance with 37 C.R.F. 1.97(b)(1), and as this Information Disclosure Statement is being prior to the issuance of a first action on the merits of the application, no


additional fee or statement is required.

In accordance with 37 C.F.R. 1.97(g) and 37C.F.R.1.97(h), filing of this Information disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 34 C.F.R. 1.56(b).

The Examiner is requested to make the attached references of record and to consider these references along with such other references deemed pertinent as a result of the Examiner's own independent search and examination.


Respectfully submitted,

Date: January 30, 2007



D. Peter Hochberg
Reg. No. 24,603

D. Peter Hochberg Co., L.P.A.
1940 E.6th Street – 6th Floor
Cleveland, OH 44114
(216) 771-3800
DPH/SM



FORM PTO-1449

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Joachim Moormann, et al.
Serial No. : 10/580,443
Filing Date : May 23, 2006
Examiner :
Group Art Unit : 1614
Title : USE OF DEOXYPEGANINE FOR TREATING
SCHIZOPHRENIC PSYCHOSES
Attorney File : RO4245US (#90568)

Mail Stop Amendment
Commissioner for Patents
P O Box 1450
Alexandria, Virginia, 22313-1450

U S PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name
_____	6,548,510	4/15/2003	Asmussen, et al.
_____	6,558,696	5/6/2003	Hille, et al.
_____	6,599,511	7/29/2003	Asmussen, et al.
_____	6,436,937	8/20/2002	Asmussen, et al.
_____	6,548,510	4/15/2006	Asmussen, et al.

U.S. Published Applications

Examiner Initial	Document Number	Date	Name
_____	2005/0009813	1/13/2005	Moormann, et al.

Examiner Initial	Document Number	<u>Foreign Patent Documents</u>		Translation (Yes/No)
		Date	Country	
_____	199 06 978 (corresponds to US '511)	8/7/2004	DE	No
_____	199 06 979 (corresponds to US '510)	8/7/2004	DE	No
_____	199 06 977 (corresponds to US '696)	6/15/2000	DE	No
_____	199 06 975 (corresponds to US '937)	4/15/2004	DE	No
_____	101 63 667 (corresponds to US '813)	7/10/2003	DE	No
_____	00/48445	8/24/2000	WO	No
_____	00/48582	8/24/2000	WO	No
_____	00/48599	8/24/2000	WO	No
_____	03/053445	7/3/2003	WO	No

Other Prior Art (Inc. Author, Title, Date, Pertinent Pages, Etc)

Examiner Initial	Document
_____	Chowdhury, et al.; "Synthesis & Biological Activities of two New, <i>Ind. J. Chem.</i> 24B, 789-790 (1985)
_____	Deutsch, et al., "Modulation of MK0801-elicited mouse popping behaviour by galantamine is complex and dose-dependent;" <i>Life Sciences</i> 73, 2333-2361 (2003)
_____	Lewine, et al., "Negative Symptoms and Platelet Monoamine Oxidase Activity in Male Schizophrenic Patients;" <i>Psychiatry Res.</i> 12, 99-109 (1984)
_____	Ojo, et al.; "Synthesis of 1, 2, 3, 9-Tetrahydro-7-Bromo-6- Hydroxy-5-Methoxypyrrolo-[2, 1-b]-Quinazoline: A New Analog of Deoxyvasicine;" <i>Synthetic Commun.</i> 25(4), 569-572 (1995)

Schildkraut et al., "Platelet Monoamine Oxidase Activity in Subgroups of Schizophrenic Disorders;" *Schizophr. Bull.* 6, 220-225(1980)

Schildkraut et al., "Elevated Platelet MAO Activity in Schizophrenia-Related Depressive Disorders;" Schildkraut et al., *Am J Psychiatry* 135, 110-112(1978)

Vovin, R.Y., et al.; "Correction of Akinetic-Abulic Syndrome in Schizophrenics Using Cholinotropic Drugs;" *Zurnal Nevropatologii I Psihatrii Imeni S.S. Korsakova, Izdatel' Stvo Meditsina*; Moscow, Russia; Vol. 91, No. 2 (Feb. 1991), pages 111-115 *

Drug Des. Disc. 14, 1-14 (1996) *

Examiner

Date Considered:

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant

* Denotes a copy will follow